, ECSTRA Team, CRESS UMR 1153, INSERM, 1205.

, Hôpital Barbois, Vandoeuvre-les

J. Vose, J. Armitage, and D. Weisenburger, International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes, J Clin Oncol, vol.26, pp.4124-4154, 2008.

A. N. Abouyabis, P. J. Shenoy, and R. Sinha, A systematic review and metaanalysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma, ISRN Hematol, vol.623924, p.16, 2011.

N. Schmitz and L. De-leval, How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future, Br J Haematol, vol.176, pp.851-66, 2017.

V. Mak, J. Hamm, and M. Chhanabhai, Survival of patients with peripheral Tcell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors, J Clin Oncol, vol.31, pp.1970-1976, 2013.

B. Coiffier, B. Pro, and H. M. Prince, Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy, J Clin Oncol, vol.30, pp.631-637, 2012.

M. Lamarque, C. Bossard, and A. Contejean, Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients, Haematologica, vol.101, issue.3, pp.103-109, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01419525

J. Gauthier, S. Chantepie, and K. Bouabdallah, Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), Bull Cancer, vol.104, pp.112-132, 2017.

M. A. Kharfan-dabaja, A. Kumar, and E. Ayala, Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation, Biol Blood Marrow Transplant, vol.23, pp.1826-1864, 2017.

G. Fossard, F. Broussais, and I. Coelho, Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers, Ann Oncol, vol.29, pp.715-738, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01759926

S. I. Park, S. M. Horwitz, and F. M. Foss, The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study, Cancer, vol.29, p.31861, 2019.

F. D'amore, T. Relander, and G. F. Lauritzsen, Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01, J Clin Oncol, vol.30, pp.3093-3102, 2012.

P. Reimer, T. Rudiger, and E. Geissinger, Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study, J Clin Oncol, vol.27, pp.106-119, 2009.

M. Alcantara, M. Tesio, and C. H. June, CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic Tcells, Leukemia, vol.32, pp.2307-2322, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01903063

A. C. Mamez, L. Souchet, and D. Roos-weil, Graft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation, Bone Marrow Transplant, vol.50, pp.304-310, 2015.

L. Gouill, S. Milpied, N. Buzyn, and A. , Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire, J Clin Oncol, vol.26, pp.2264-71, 2008.

P. Corradini, A. Dodero, and F. Zallio, Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells, J Clin Oncol, vol.22, pp.2172-2178, 2004.

A. C. Mamez, V. Levy, and P. Chevallier, Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC), Bone Marrow Transplant, vol.51, pp.358-64, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01299298

J. A. Kanakry, Y. L. Kasamon, and C. D. Gocke, Outcomes of related donor HLAidentical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma, Biol Blood Marrow Transplant, vol.19, pp.602-608, 2013.

D. Przepiorka, D. Weisdorf, and P. Martin, consensus conference on acute GVHD grading, Bone Marrow Transplant, vol.15, pp.825-833, 1994.

S. M. Smith, L. J. Burns, and K. Van-besien, Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma, J Clin Oncol, vol.31, pp.3100-3109, 2013.

F. D'amore, P. Gaulard, and L. Trumper, Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.108, 2015.

J. El-asmar, T. Reljic, and E. Ayala, Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a systematic review/meta-analysis, Biol Blood Marrow Transplant, vol.22, pp.802-816, 2016.

M. Loirat, P. Chevallier, and C. Leux, Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center, Ann Oncol, vol.26, pp.386-92, 2015.

P. Corradini, U. Vitolo, and A. Rambaldi, Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma, Leukemia, vol.28, pp.1885-91, 2014.

S. Mercadal, J. Briones, and B. Xicoy, Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma, Ann Oncol, vol.19, pp.958-63, 2008.

N. Shmitz, L. Truemper, and M. Ziepert, First-line therapy of T-cell lymphoma: allogeneic or autologous transplantation for consolidation-final results of the AATT study, J Clin Oncol, vol.37, pp.7503-7506, 2019.

J. Zain, J. M. Palmer, and M. Delioukina, Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control, Leuk Lymphoma, vol.52, pp.1463-73, 2011.

C. Kyriakou, C. Canals, and J. Finke, Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation, J Clin Oncol, vol.27, pp.3951-3959, 2009.

E. D. Jacobsen, H. T. Kim, and V. T. Ho, A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome, Ann Oncol, vol.22, pp.1608-1621, 2011.

J. D. Goldberg, J. F. Chou, and S. Horwitz, Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant, Leuk Lymphoma, vol.53, pp.1124-1133, 2012.

A. Dodero, F. Spina, and F. Narni, Allogeneic transplantation following a reducedintensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect, Leukemia, vol.26, pp.520-526, 2012.

M. Delioukina, J. Zain, and J. M. Palmer, Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas, Bone Marrow Transplant, vol.47, pp.65-72, 2012.

A. Czajczynska, A. Gunther, and R. Repp, Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma, Biol Blood Marrow Transplant, vol.19, pp.1632-1639, 2013.

N. Schmitz, G. Lenz, and M. Stelljes, Allogeneic hematopoietic stem cell transplantation (HSCT) for T-cell lymphomas, Blood, vol.26, pp.2018-2019, 2018.

J. Y. Zhang, R. Briski, and S. Devata, Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL), Am J Hematol, vol.93, pp.394-400, 2018.

G. Damaj, F. Malard, and C. Hulin, Efficacy of bendamustine in relapsed/ refractory myeloma patients: results from the French compassionate use program, Leuk Lymphoma, vol.53, pp.632-636, 2012.

O. A. O'connor, L. Falchi, and J. K. Lue, Oral 5-azacytidine and romidepsin exhibit marked activity in patients with ptcl: a multicenter phase i study, 2019.

O. A. O'connor, B. Pro, and L. Pinter-brown, Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study, J Clin Oncol, vol.29, pp.1182-1191, 2011.

P. L. Zinzani, F. Venturini, and V. Stefoni, Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome, Ann Oncol, vol.21, pp.860-863, 2010.

N. Epperla, K. W. Ahn, and C. Litovich, Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis, J Hematol Oncol, vol.12, p.6, 2019.

A. S. Kanate, A. Digilio, and K. W. Ahn, Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis, Br J Haematol, vol.182, pp.916-936, 2018.

B. Pro, R. Advani, and P. Brice, Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma, Blood, vol.132, issue.4, pp.2709-2726, 2017.

N. Ghosh, R. Karmali, and V. Rocha, Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis, J Clin Oncol, vol.34, pp.3141-3150, 2016.

A. K. Zoellner, S. Fritsch, and D. Prevalsek, Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma, Bone Marrow Transplant, vol.50, pp.679-84, 2015.

H. Mediwake, K. Morris, and C. Curley, Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/ refractory CD30 positive lympho-proliferative disorders: a single centre experience, Intern Med J, vol.47, pp.574-582, 2017.

K. N. Koh, H. J. Im, and J. K. Suh, Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy posttransplantation, Pediatr Blood Cancer, vol.62, pp.1063-1068, 2015.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations